Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’
This article was originally published in The Pink Sheet Daily
Executive Summary
Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.